NDLI: Stereotactic body radiotherapy for localized prostate cancer

Content Provider	Springer Nature : BioMed Central
Author	Vuolukka, Kristiina Auvinen, Päivi Tiainen, Erno Palmgren, Jan-Erik Heikkilä, Janne Seppälä, Jan Aaltomaa, Sirpa Kataja, Vesa
Abstract	Background The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT. Methods This non-selected, real-life patient cohort included 213 patients with localized PCa treated with a robotic SBRT device during 2012–2015. Results The median follow-up was 64 months (range, 10–85 months), and all risk-groups were represented as 47 (22.1%), 56 (26.3%) and 110 (51.6%) patients were classified into D’Amico risk stratification of low, intermediate and high-risk groups, respectively. Androgen deprivation therapy (ADT) was administered to 64.3% of the patients. At cut-off, the biochemical relapse-free survival (bRFS) was 100, 87.5 and 80.0% for patients at low, intermediate and high-risk (p = 0.004), and 92.5, 84.2 and 66.7% for patients with Gleason score ≤ 6, 7 and ≥ 8, respectively (p = 0.001). The actuarial 5-year overall survival (OS) rates were 97.9, 96.4 and 88.6% in the low, intermediate and high-risk groups, respectively, and at the cut-off, the disease-specific survival (DSS) rate of the whole cohort was high (99.1%), as only two high-risk patients died due to PCa. Conclusion Our present results of SBRT delivered with CyberKnife produced excellent long-term bRFS, OS and DSS outcomes among patients with localized PCa. We conclude that SBRT provides an efficient and convenient treatment option for patients with localized PCa, irrespective of the risk-group.
Related Links	https://ro-journal.biomedcentral.com/counter/pdf/10.1186/s13014-020-01608-1.pdf
Ending Page	8
Page Count	8
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s13014-020-01608-1
Journal	Radiation Oncology
Issue Number	1
Volume Number	15
Language	English
Publisher	BioMed Central
Publisher Date	2020-07-14
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Radiotherapy Imaging Radiology Prostate cancer Radiation therapy Stereotactic body radiotherapy
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Oncology
Journal Impact Factor	3.3/2023
5-Year Journal Impact Factor	3.6/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer

Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis

Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results

Similar Documents

Safety of stereotactic body radiation therapy for localized prostate cancer without treatment planning MRI

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer

Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis

Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results